Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Common Equity (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Common Equity for 5 consecutive years, with $53.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 284.81% year-over-year to $53.5 million, compared with a TTM value of $53.5 million through Dec 2025, up 284.81%, and an annual FY2025 reading of $53.5 million, up 284.81% over the prior year.
  • Common Equity was $53.5 million for Q4 2025 at Aligos Therapeutics, down from $71.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $217.0 million in Q3 2021 and bottomed at -$29.0 million in Q4 2024.
  • Average Common Equity over 5 years is $103.7 million, with a median of $97.0 million recorded in 2023.
  • The sharpest move saw Common Equity tumbled 131.47% in 2024, then soared 284.81% in 2025.
  • Year by year, Common Equity stood at $184.7 million in 2021, then tumbled by 43.76% to $103.9 million in 2022, then decreased by 11.38% to $92.1 million in 2023, then plummeted by 131.47% to -$29.0 million in 2024, then skyrocketed by 284.81% to $53.5 million in 2025.
  • Business Quant data shows Common Equity for ALGS at $53.5 million in Q4 2025, $71.8 million in Q3 2025, and $101.9 million in Q2 2025.